Introduction Neovascular age-related macular degeneration (nAMD) involves abnormal choroidal neovascularization leading to central vision loss and is the leading cause of legal blindness in those aged 65 and older.1,2 The current standard of care for nAMD is serial vascular endothelial growth factor (VEGF) inhibitor intravitreal injections at varying treatment intervals.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile